Most cessation resources-apps, programs, clinical interventions-treat addiction as a single phenomenon with a single solution set: motivational frameworks, behavioral tools, willpower cultivation, generic "stress management."
These resources are not wrong that these tools are useful. They are wrong that the specific neuroscience of each substance is irrelevant.
The Three Withdrawal Profiles
Nicotine withdrawal: Primarily cholinergic and dopaminergic. Acute phase (72 hours). Secondary dopamine deficit phase (weeks 2-4). Oral/behavioral habit component separate from pharmacology. Evidence-based intervention: α4β2 partial agonists, glutamate normalization, behavioral substitution.
Cannabis withdrawal: Primarily endocannabinoid system dysfunction. Dominates through sleep (REM rebound), appetite (ECS appetite signaling), mood (CB1 anxiolytic function), and cognition (prefrontal CB1). Evidence-based intervention: CB1 recovery support (DHA/EPA), sleep protocol (Magnesium L-Threonate, Apigenin), anxiety management (Ashwagandha, L-Theanine).
Alcohol withdrawal: Primarily GABA-A/NMDA imbalance, with medical danger in severe cases. Dopamine system disruption. Nutritional deficiencies (thiamine, B6, B12). Evidence-based intervention: GABA-A support (Magnesium), NMDA normalization, thiamine repletion, Kudzu for craving.
These are not variations on the same theme. They are distinct neurological events requiring distinct responses.
The Generic Cessation Failure Mode
A behavioral cessation app with mindfulness exercises and willpower tracking provides:
- Motivational tools: helpful across all substances
- Behavioral CBT framework: helpful across all substances
- No pharmacological support: unhelpful for any substance
- No substance-specific biology: unhelpful for understanding what is happening
The person quitting nicotine using only behavioral tools lacks cytisine during the 72-hour nAChR storm. The person quitting cannabis lacks sleep support during the REM rebound. The person quitting alcohol lacks thiamine during a potentially medically dangerous situation.
Generic tools leave the specific biology unaddressed.
The Evidence Asymmetry
The most important treatments in cessation are not motivational-they are pharmacological and nutritional. The evidence for:
- Cytisine in nicotine cessation: NNT (number needed to treat) of approximately 8-12 for 6-month abstinence
- NAC in cannabis cessation: significant abstinence improvement in all three RCTs
- Kudzu in alcohol craving: significant reduction in 3 RCTs
- Thiamine in alcohol withdrawal: prevents irreversible neurological damage
These are specific, evidence-based, substance-specific interventions. No generic cessation app provides them.
The Relapsd Argument
Relapsd is built on a single scientific premise: the substance defines the withdrawal, and the withdrawal defines the intervention.
This is not a marketing claim. It is the conclusion of reading the cessation literature carefully. Every clinical trial of cessation intervention is conducted in a substance-specific population. No trial has ever compared "generic cessation" to "substance-specific cessation" because no clinical researcher would design such a trial-the question is considered settled.
Substance-specific intervention is standard in clinical cessation medicine. It is not standard in consumer cessation products. That gap is what Relapsd exists to close.